Phlorotannin Fraction Induces Pluripotency in Mesenchymal Stem Cells
Solution Overview
Problem
Current methods for inducing pluripotency stem cells from mesenchymal stem cells face challenges such as low efficiency, stability issues, and ethical concerns, particularly in the use of embryonic stem cells, and existing compositions for dedifferentiation do not clearly identify the effective components responsible for pluripotency induction.
Innovation Solution
A medium composition containing a phlorotannin fraction, specifically bieckol compounds extracted from brown algae like Ecklonia cava, is used to dedifferentiate mesenchymal stem cells into induced pluripotency stem cells, which are then differentiated into various cell types for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic stem cells are used to achieve pluripotency, then differentiation ability into all cell types is improved, but ethical issues arise due to embryo destruction
Solution Approach 1:
The patent creates induced pluripotent stem cells (iPSCs) by reprogramming adult somatic cells to mimic embryonic stem cells. This copying approach replicates the pluripotency and differentiation capabilities of embryonic stem cells without using actual embryos, thereby resolving the ethical contradiction while maintaining the desired adaptability.
Solution Approach 2:
The patent employs gene reprogramming techniques that alter the genetic expression parameters of adult cells, transforming them into pluripotent state. By changing the cellular parameters through introduced genes (such as Oct4, Sox2, Klf4, c-Myc), the cell's differentiation potential is enhanced without ethical concerns associated with embryonic destruction.
2Object-affected harmful factors
If adult stem cells are used to avoid ethical issues, then ethical problems are reduced, but differentiation ability and multipotency are limited
Solution Approach 1:
The patent transforms adult stem cells with limited differentiation potential into induced pluripotent stem cells by altering their genetic parameters. Through introduction of specific reprogramming genes, the cells undergo a parameter change that expands their differentiation capacity to match embryonic stem cells while maintaining the ethical advantage of using adult cell sources.
Solution Approach 2:
The patent makes adult stem cells universally capable of differentiating into multiple cell types by reprogramming them to a pluripotent state. This multi-functional transformation allows the same adult cell source to generate various cell lineages, combining the ethical advantage of adult cells with the versatility of embryonic stem cells.
3Adaptability or versatility
If gene factor reprogramming is used to induce dedifferentiation, then pluripotency can be achieved, but cancer risk increases due to oncogene usage
Solution Approach 1:
The patent extracts and uses only the essential reprogramming genes (Oct4, Sox2, Klf4, c-Myc) from the full set of oncogenes. By selectively taking out only the necessary genes for pluripotency induction and excluding other oncogenic elements, the method achieves reprogramming while minimizing cancer risk associated with comprehensive oncogene usage.
Solution Approach 2:
The patent applies partial action by using a limited subset of reprogramming genes rather than complete oncogenic transformation. This partial approach provides sufficient pluripotency induction while reducing the excessive oncogenic burden that would lead to higher cancer risk, achieving a balanced reprogramming strategy.
4Adaptability or versatility
If fusion with ES cell is used for reprogramming, then pluripotency can be achieved, but cell stability is compromised due to dual gene pairs
Solution Approach 1:
The patent extracts and uses only the essential reprogramming genes (Oct4, Sox2, Klf4, c-Myc) from the full set of oncogenes. By selectively taking out only the necessary genes for pluripotency induction and excluding other oncogenic elements, the method achieves reprogramming while minimizing cancer risk associated with comprehensive oncogene usage.
Solution Approach 2:
The patent applies partial action by using a limited subset of reprogramming genes rather than complete oncogenic transformation. This partial approach provides sufficient pluripotency induction while reducing the excessive oncogenic burden that would lead to higher cancer risk, achieving a balanced reprogramming strategy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a medium composition for the dedifferentiation of induced pluripotency stem cells, containing a phlorotannin fraction extracted and isolated from one type of brown algae selected from the group consisting of Ecklonia cava, Dictyopteris prolifera, Dictyota coriacea, Sargassum horneri, Ishige okamurai and the like. In addition, the present invention relates to a method for preparing induced pluripotency stem cells by using the medium composition. Induced pluripotency stem cells can be safely, easily and effectively prepared by using mesenchymal stem cells by using the medium composition of the present invention, and the prepared induced pluripotency stem cells can be differentiated into various cells, and thus can be useful as a cell therapeutic agent.
